Allicia C. Girvan

1.2k citations

31 papers · 826 indexed · h-index 12

Co-authors: Shelia D. Thomas Paula J. Bates Yun Teng Lavona Casson William M. Pierce Shirish Barve Jon B. Klein Simone Jüliger
Topics: Lung Cancer Treatments and Mutations (10 papers)Hepatocellular Carcinoma Treatment and Prognosis (7 papers)Lung Cancer Research Studies (6 papers)
Cited by: Oncology Molecular Biology Hepatology
Journals: Journal of Biological Chemistry Journal of Clinical Oncology Cancer Research
Partner nations: United States Germany Spain

In The Last Decade

Allicia C. Girvan

30 papers receiving 812 citations

Peers

Countries citing papers authored by Allicia C. Girvan

Since Specialization

Citations

This map shows the geographic impact of Allicia C. Girvan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Allicia C. Girvan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Allicia C. Girvan more than expected).

Fields of papers citing papers by Allicia C. Girvan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Allicia C. Girvan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Allicia C. Girvan. The network helps show where Allicia C. Girvan may publish in the future.

Co-authorship network of co-authors of Allicia C. Girvan

This figure shows the co-authorship network connecting the top 25 collaborators of Allicia C. Girvan. A scholar is included among the top collaborators of Allicia C. Girvan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Allicia C. Girvan. Allicia C. Girvan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Risk thresholds for patients to switch between daily tablets and biweekly infusions in second-line treatment for advanced hepatocellular carcinoma: a patient preference study 2023 ·BMC Cancer ·Neehar D. Parikh,Allicia C. Girvan,(unknown),(unknown),Jiat Ling Poon,Sangmi Kim,Anindya Chatterjee,Marco Boeri	2
2	Physician- and Patient-Reported Symptom Concordance and Association with Quality of Life in Hepatocellular Carcinoma 2022 ·Future Oncology ·Andrea Leith,Urpo Kiiskinen,Allicia C. Girvan,Min‐Hua Jen,(unknown),A. Rider,(unknown),James Piercy	2
3	PCN53 HEALTHCARE RESOURCE UTILIZATION AND COSTS IN PATIENTS TREATED WITH TYROSINE KINSASE INHIBITORS AS SECOND-LINE TREATMENT FOR ADVANCED HEPATOCELLULAR CARCINOMA IN THE UNITED STATES 2020 ·Value in Health ·(unknown),(unknown),Zhanglin Lin Cui,(unknown),Allicia C. Girvan	1
4	Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trials 2020 ·ESMO Open ·Andrew X. Zhu,Ryan David Nipp,Richard S. Finn,Peter R. Galle,Josep M. Llovet,Jean-Frédéric Blanc,Takuji Okusaka,Ian Chau,David Cella,Allicia C. Girvan,(unknown),Lee Bowman,Chunxiao Wang,Yanzhi Hsu,Paolo Abada,Masatoshi Kudo	21
5	Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes 2019 ·Clinical Cancer Research ·Valeria Santini,David Valcárcel,Uwe Platzbecker,Rami S. Komrokji,Ann Cleverly,Michael Lahn,Jan Janßen,Yumin Zhao,Alan Y. Chiang,Aristoteles Giagounidis,Susan C. Guba,Ivelina Gueorguieva,Allicia C. Girvan,(unknown),Tushar D. Bhagat,Kith Pradhan,Ulrich Steidl,Ashwin Sridharan,Britta Will,Amit Verma	60
6	PCN524 EUROPEAN REAL-WORLD TREATMENT PATTERNS OF SYSTEMIC THERAPIES FOR SECOND LINE (2L) HEPATOCELLULAR CARCINOMA (HCC) PATIENTS WHO PREVIOUSLY RECEIVED SORAFENIB 2019 ·Value in Health ·Urpo Kiiskinen,A. Rider,Andrea Leith,(unknown),Allicia C. Girvan,(unknown),(unknown),Min‐Hua Jen	1
7	PCN366 - QUALITATIVE PATIENT INTERVIEWS TO SUPPORT THE FACT HEPATOBILIARY SYMPTOM INDEX-8 AMONG PATIENTS WITH HEPATOCELLULAR CARCINOMA AND ELEVATED BASELINE ALPHA-FETOPROTEIN 2018 ·Value in Health ·Julia Gable,David W. Ayer,Allicia C. Girvan,Lee Bowman,(unknown),(unknown),Emily Evans,David Cella	1
8	Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Patient reported outcome results across two phase III studies (REACH-2 and REACH) 2018 ·Annals of Oncology ·Andrew X. Zhu,Richard S. Finn,Peter R. Galle,Josep M. Llovet,Jean‐Frédéric Blanc,Takuji Okusaka,Ian Chau,David Cella,Allicia C. Girvan,Julia Gable,Lee Bowman,Yanzhi Hsu,(unknown),Masatoshi Kudo	7
9	Treatment patterns and costs of care for patients diagnosed with hepatocellular carcinoma (HCC) in the United States (U.S.) 2018 ·Annals of Oncology ·(unknown),Zhanglin Lin Cui,(unknown),(unknown),Allicia C. Girvan,Paolo Abada	5
10	Reweighting Rct Evidence To Better Reflect Real Life: A Case Study of The Innovation Medicines Initiative 2016 ·Value in Health ·Michael Happich,Alan Brnabic,D Faries,Keith R. Abrams,Katherine B. Winfree,Allicia C. Girvan,Páll Jónsson,Joseph A. Johnston,Mark Belger	2
11	Non-small cell lung cancer patients with brain metastases treated with first-line platinum-doublet chemotherapy: Analysis from the European FRAME study 2015 ·Lung Cancer ·Denis Moro‐Sibilot,Egbert F. Smit,Javier de Castro,Krzysztof Leśniewski-Kmak,Joachim G.J.V. Aerts,(unknown),(unknown),(unknown),Yulia Dyachkova,Karen Smith,Allicia C. Girvan,Carla Visseren‐Grul,Philipp A. Schnabel	54
12	Outcomes and resource use of non-small cell lung cancer (NSCLC) patients treated with first-line platinum-based chemotherapy across Europe: FRAME prospective observational study 2015 ·Lung Cancer ·Denis Moro‐Sibilot,Egbert F. Smit,Javier de Castro,Krzysztof Leśniewski-Kmak,Joachim G.J.V. Aerts,(unknown),(unknown),(unknown),Yulia Dyachkova,Karen Smith,(unknown),Allicia C. Girvan,Carla Visseren‐Grul,Philipp A. Schnabel	55
13	Cisplatin and carboplatin-based chemotherapy in the first-line treatment of non-small cell lung cancer: Analysis from the European FRAME study 2015 ·Lung Cancer ·Egbert F. Smit,Denis Moro‐Sibilot,Javier de Castro,Krzysztof Leśniewski-Kmak,Joachim G.J.V. Aerts,(unknown),(unknown),(unknown),Yulia Dyachkova,Karen Smith,Allicia C. Girvan,Carla Visseren‐Grul,Philipp A. Schnabel	13
14	Glioblastoma treatment patterns, survival, and healthcare resource use in real-world clinical practice in the USA 2015 ·Drugs in Context ·Allicia C. Girvan,(unknown),Li Lin,Anna Kaltenboeck,Jasmina Ivanova,Maria Koh,(unknown),Eleanor Hayes‐Larson,Michael Lahn	15
15	Prospective Observational Comparison of Clinical Outcomes Between African-American and Caucasian Patients Receiving Second-Line Treatment With Pemetrexed for Advanced Non–Small-Cell Lung Cancer 2013 ·Clinical Lung Cancer ·Eduardo J. Pennella,Coleman K. Obasaju,Gerhardt Pohl,Gerson Peltz,Allicia C. Girvan,Katherine B. Winfree,(unknown),Martin Marciniak,Mark S. Walker,Edward J. Stepanski,Lee S. Schwartzberg,Alex A. Adjei	5
16	Treatment patterns among cancer patients with anemia who do not respond to erythropoietin-stimulating agents. 2013 ·Journal of Clinical Oncology ·Allicia C. Girvan,Yiu-Keung Lau,Lee Bowman,Gerhardt Pohl,Pamela Landsman‐Blumberg,Nianwen Shi,Helen Varker	1
17	Influence of histology and biomarkers on first-line treatment of advanced non-small cell lung cancer in routine care setting: Baseline results of an observational study (FRAME) 2012 ·Lung Cancer ·Philipp A. Schnabel,Egbert F. Smit,Javier de Castro,(unknown),Joachim G.J.V. Aerts,(unknown),Carla Visseren‐Grul,Yulia Dyachkova,(unknown),Allicia C. Girvan,Denis Moro‐Sibilot	16
18	Treatment Rationale and Study Design for the PointBreak Study: A Randomized, Open-label Phase III Study of Pemetrexed/Carboplatin/Bevacizumab Followed by Maintenance Pemetrexed/Bevacizumab Versus Paclitaxel/Carboplatin/Bevacizumab Followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer 2009 ·Clinical Lung Cancer ·Jyoti D. Patel,Philip Bonomi,Mark A. Socinski,Ramaswamy Govindan,Shengyan Hong,Coleman K. Obasaju,Eduardo J. Pennella,Allicia C. Girvan,Susan C. Guba	62
19	AGRO100 inhibits activation of nuclear factor-κB (NF-κB) by forming a complex with NF-κB essential modulator (NEMO) and nucleolin 2006 ·Molecular Cancer Therapeutics ·Allicia C. Girvan,Yun Teng,Lavona Casson,Shelia D. Thomas,Simone Jüliger,Mark W. Ball,Jon B. Klein,William M. Pierce,Shirish Barve,Paula J. Bates	202
20	Inhibition of DNA Replication and Induction of S Phase Cell Cycle Arrest by G-rich Oligonucleotides 2001 ·Journal of Biological Chemistry ·Xiaohua Xu,(unknown),Shelia D. Thomas,(unknown),Allicia C. Girvan,W. Glenn McGregor,John O. Trent,Donald M. Miller,Paula J. Bates	136

About Allicia C. Girvan

Allicia C. Girvan is a scholar working on Hepatology, Oncology and Cancer Research, having authored 31 papers that have together received 826 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (10 papers), Hepatocellular Carcinoma Treatment and Prognosis (7 papers) and Lung Cancer Research Studies (6 papers). The work is most often cited by research in Oncology (239 citations), Molecular Biology (505 citations) and Hepatology (50 citations). Allicia C. Girvan has collaborated with scholars based in United States, Germany and Spain. Frequent co-authors include Shelia D. Thomas, Paula J. Bates, Yun Teng, Lavona Casson, William M. Pierce, Shirish Barve, Jon B. Klein, Simone Jüliger, Mark W. Ball and Mingwei Qian. Their work appears in journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact